- Current report filing (8-K)
February 10 2009 - 12:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (date of earliest event reported): February 10, 2009
Cougar
Biotechnology, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
001-33871
|
|
20-2903204
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
10990
Wilshire Blvd, Suite 1200
Los
Angeles, CA 90024
|
(Address of principal executive offices) (Zip Code)
|
(310) 943-8040
(Registrant’s telephone number, including area
code)
N/A
(Former name or former address, if changed
since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
On February 10, 2009, Cougar Biotechnology, Inc. (the “Company”) issued
a press release announcing that it had reached an agreement with the
Food and Drug Administration under a special protocol assessment
relating to its planned Phase III clinical trial of the Company’s lead
drug candidate CB7630 (abiraterone acetate) in patients with
chemotherapy naïve castration resistant prostate cancer. A copy of the
press release is attached hereto as Exhibit 99.1 and incorporated herein
by reference
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
99.1
|
|
Press release dated February 10, 2009.
|
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
COUGAR BIOTECHNOLOGY, INC.
|
|
|
|
|
|
|
Date:
|
February 10, 2009
|
By:
|
|
/s/ Charles R. Eyler
|
|
|
|
|
Charles R. Eyler
|
|
|
|
|
Sr. Vice President, Finance
|
INDEX TO EXHIBITS FILED WITH THIS REPORT
Exhibit No.
|
|
Description
|
99.1
|
|
Press release dated February 10, 2009.
|
3
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Cougar Biotechnology (MM) (NASDAQ): 0 recent articles
More News Articles